Per a court order, HHS is required to restore this website to its version as of 12:00 AM on January 29, 2025. Information on this page may be modified and/or removed in the future subject to the terms of the court’s order and implemented consistent with applicable law. Any information on this page promoting gender ideology is extremely inaccurate and disconnected from truth. The Trump Administration rejects gender ideology due to the harms and divisiveness it causes. This page does not reflect reality and therefore the Administration and this Department reject it.

U.S. Department of Health and Human Services Office of Disease Prevention and Health Promotion

Anti-vascular Endothelial Growth Factor for Diabetic Macular Oedema: A Network Meta-Analysis

About this resource:

Systematic Review

Source: The Cochrane Collaborative

Last Reviewed: October 2018

Workgroups: Vision Workgroup, Diabetes Workgroup

In this Cochrane systematic review, the Cochrane Collaborative found that anti-vascular endothelial growth factor medicines prevent vision loss and improve vision in people with diabetic macular edema. These medicines — aflibercept, bevacizumab, and ranibizumab — are injected into the eye to slow the growth of new blood vessels and reduce swelling at the back of the eye. Researchers found some evidence that aflibercept is more effective than bevacizumab and ranibizumab.

Read more about this resource

Objectives related to this resource (1)

Reduce vision loss from diabetic retinopathy — V‑04
Baseline only

Suggested Citation

1.

Virgili, G., Parravano, M., Evans, J. R., Gordon, I., & Lucenteforte, E. (2018). Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Cochrane Database of Systematic Reviews, 2018 (6). DOI: 10.1002/14651858.CD007419.pub6.